Recon

NJR of England & Wales Confirms Success of DePuy Joint Replacement Products

WARSAW, IN – SEPTEMBER 19, 2011 – DePuy Orthopaedics, Inc. (DePuy), a global leader in devices for joint replacement, is pleased that results released in the 2011 Annual Report of the National Joint Registry of England and Wales (UK NJR) confirm the continued clinical success of current DePuy hip and knee joint replacement products. These devices help patients who have been affected by pain, disability and a loss of mobility return to their daily activities.

“The 2011 UK National Joint Registry report provides valuable information about many of the DePuy hip and knee products currently on the market,” said Andrew Ekdahl, President, DePuy Orthopaedics, Inc. “In each case, the report confirms that those products continue to perform well. We’re proud of our 40-year heritage of developing leading joint replacement products and technologies that have helped so many patients around the world.”

The UK NJR data also corroborates previous data and independent testing results that demonstrate the success of DePuy hip and knee products currently on the market.

Hip Replacement
Within the 2011 UK NJR, DePuy Orthopaedics’ currently marketed hip replacement systems continue to demonstrate success.

According to the report, more than 97% of PINNACLE® Acetabular Cup System and CORAIL® Total Hip System combinations were still in place 5 years after they were implanted, exceeding the 5-year cementless total hip replacement survivorship rate of 96% across all hip replacement products and manufacturers.

Together, the CORAIL Hip System and the PINNACLE Cup System continue to be the most commonly implanted construct in England and Wales, according to the data in the 2011 report.
·         The CORAIL Hip System was the most implanted cementless stem with 15,239 implantations last year.
·         The PINNACLE Cup System was the most implanted cementless cup with 14,246 implantations last year.

DePuy Orthopaedics’ cemented total hip replacement systems also continue to perform well according to the 2011 report.

This most recent report from the UK NJR reaffirms the findings from previous years and is consistent with DePuy’s own independent analysis of the performance of our total hip systems. The data has consistently shown that these products are safe and effective options for patients who are candidates for hip replacements.

While the UK NJR report does not break down brand data by bearing surface, clinical evidence and experience demonstrate that the PINNACLE® ULTAMET® Metal-on-Metal Articulation System successfully reduces pain and improves mobility in the vast majority of hip replacement patients and has survivorship rates that are consistent with or better than other metal-on-metal products. According to the Australian Orthopaedic Association National Joint Replacement Registry 2010 annual report, more than 96% of PINNACLE ULTAMET Metal-on-Metal Bearings were still in place at five years.

Knee Replacement
Within the 2011 UK NJR, DePuy’s PFC® SIGMA® Knee System continues to perform well, as does the LCS® Mobile Bearing Knee System.

The 2011 UK NJR annual report data shows that the PFC SIGMA Knee System was the most implanted knee in England and Wales in 2010 with 24,215 implantations. More than 98% of PFC SIGMA Knee Systems were still in place 5 years after they were implanted. In addition, the LCS Mobile Bearing Knee System was implanted 2,772 times in 2010, with a 5-year survivorship rate of 97%. Both are in line with the industry-wide knee replacement survivorship rate of 97%.

Important Safety Information
As with any medical treatment, individual results may vary. The performance of hip and knee replacements depends on age, weight, activity level and other factors. There are potential risks and recovery takes time. People with conditions limiting rehabilitation should not have this surgery. Only an orthopaedic surgeon can tell if hip or knee replacement is right for an individual patient.

About DePuy Orthopaedics, Inc.
DePuy Orthopaedics, Inc. is a leading global provider of orthopaedic devices for hip, knee, extremities and trauma, as well as bone cement and operating room products. It is part of the DePuy Companies of Johnson & Johnson, which have a rich heritage of pioneering a broad range of products and solutions across the continuum of orthopaedic and neurological care. These companies are unified under one vision – NEVER STOP MOVING® – to express their commitment to bring meaningful innovation, shared knowledge and quality care to patients throughout the world.

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button